REG - hVIVO PLC - Director/PDMR Shareholding

hVIVOAnnouncement

24/04/2026 18:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260424:nRSX9139Ba&default-theme=true

RNS Number : 9139B  hVIVO PLC  24 April 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Director/PDMR Dealings

 

London, UK - 24 April 2026, hVIVO plc (AIM: HVO), a purpose-built,
full-service international clinical development partner and the world leader
in human challenge trials, has been notified that Brendan Buckley,
Non-Executive Director, has sold 2,017,000 ordinary shares of £0.001 each in
the Company ("Ordinary Shares") at a price of 8.65p per Ordinary Share.

 

Following this transaction, Brendan Buckley, who has informed the Company of
his intention not to stand for re-election at the upcoming AGM, now holds
2,000,270 Ordinary Shares in the Company.

(https://url.uk.m.mimecastprotect.com/s/7AhfCYyY0U3JENNu0fYTx9fpW?domain=investormeetcompany.com)

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

For further information please contact:

 

 hVIVO plc                                                                           +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                                                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (AIM: HVO) is a purpose-built, full-service
international clinical development partner and the global leader in human
challenge trials, serving seven of the world's ten largest biopharma
companies.

 

The Company has an end-to-end platform designed to bring important medicines
to patients faster: spanning preclinical strategy, first‑in‑human studies,
Phase II patient trials and specialist laboratory services, delivered through
a large participant database, wholly owned sites and laboratories across the
UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an
accelerated pathway to clinical proof-of-concept through four integrated
service lines: Consulting, Clinical Trials, Human Challenge Trials, and
Laboratories.

 

·    Consulting
(https://www.hvivo.com/solutions/drug-development-consulting) provides
expert-led preclinical and clinical strategy, encompassing non-clinical,
clinical, CMC, pharmacokinetics, data management, biostatistics, and
regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials (https://www.hvivo.com/solutions/clinical/) offers
Phase I/II CRO services, Phase II/III site services across the UK and Germany,
and specialist recruitment through FluCamp (http://www.flucamp.com/) ,
Europe's largest recruitment database.

·    Human Challenge Trials
(https://www.hvivo.com/solutions/human-challenge) leverages hVIVO's
state-of-the-art quarantine facility in London - the largest of its kind
worldwide - to deliver fast, controlled, high-quality efficacy data through
guaranteed viral exposure.

·    Laboratories (https://www.hvivo.com/solutions/laboratory) provides
cutting-edge virology and immunology laboratory services, including biobanking
and sample storage, supporting both challenge trials and standalone client
studies.

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Brendan Buckley
 2   Reason for notification

 a.  Position/Status                                              Non-Executive Director
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         hVIVO plc
 b.  LEI                                                          213800VT5KBM7JLIV118
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification Code

                                                                  ISIN GB00B9275X97

 b.  Nature of the transaction                                    Sale of Ordinary Shares
 c.  Price(s) and volume(s)                                       No. of Shares  Price

                                                            2,017,000      8.65p

 d.  Aggregated information

     - Aggregated Volume                                          2,017,000

     - Price                                                      8.65p
 e.  Date of the transaction                                      24 April 2026
 f.  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

2,017,000

 

8.65p

e.

Date of the transaction

24 April 2026

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDZLFLQZLFBBF



            Copyright 2019 Regulatory News Service, all rights reserved